CN108379244A - A kind of pharmaceutical composition and its preparation process for treating reversible obstructive airways disease - Google Patents
A kind of pharmaceutical composition and its preparation process for treating reversible obstructive airways disease Download PDFInfo
- Publication number
- CN108379244A CN108379244A CN201810229148.0A CN201810229148A CN108379244A CN 108379244 A CN108379244 A CN 108379244A CN 201810229148 A CN201810229148 A CN 201810229148A CN 108379244 A CN108379244 A CN 108379244A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- obstructive airways
- airways disease
- reversible obstructive
- preparation process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical compositions and its preparation process for treating reversible obstructive airways disease, and the raw material that the pharmaceutical composition of the treatment reversible obstructive airways disease is made includes salmeterol, beclomeasone propionate, filler, disintegrant, stabilizer, adhesive, accelerating agent, lubricant and solubilizer；Preparation process of the present invention is reasonable, and drug safety is high, stability is strong, and the treatment for reversible obstructive airways disease can promote Airway Remodeling, strengthen broncho-pulmonary function of organization, be suitble to large-scale industrial production.
Description
Technical field
The present invention relates to pharmaceutical engineering field more particularly to a kind of drugs for treating reversible obstructive airways disease
Composition and its preparation process.
Background technology
Reversible obstructive airways disease is one group of chronic airway obstruction disease, is the chronic disease of common respiratory system
Disease, common feature are pulmonary parenchyma and the impaired cause chronic airway obstruction of small airway, and respiratory resistance increases and pulmonary insufficiency, including
Chronic bronchitis, bronchial asthma, the diseases such as bronchiectasis.
Reversible obstructive airways disease is a kind of not fully reversible with respiratory tract sucking pernicious gas or deleterious particle cause
Flow limitation be characterized and be in carry out sexual development lung's nonspecific inflammatory disease, be world's prevention and treatment of chronic diseases emphasis it
One.Reversible obstructive airways disease is to endanger one of the principal disease of people's health now, and incidence increasingly rises, due to disease
Journey migrates, and recurrent exerbation acute exacerbation, has seriously affected the quality of life of reversible obstructive airways Disease, at present
As one of main burden of various countries' medical treatment.
Treatment for reversible obstructive airways disease, at present mostly using salmeterol powders for inhalation to combine
Administration form is used for the conventional therapy of reversible obstructive airways disease.For this purpose, we have developed a kind of new pharmaceutical composition
For treating reversible obstructive airways disease.
Invention content
The present invention provides a kind of pharmaceutical compositions and its preparation process for treating reversible obstructive airways disease；
Preparation process of the present invention is reasonable, and drug safety is high, stability is strong, and the treatment for reversible obstructive airways disease can promote
Air intake duct is remolded, and broncho-pulmonary function of organization is strengthened, and is suitble to large-scale industrial production.
To achieve the above object, technical scheme of the present invention is implemented as follows：
It is reversible that the treatment is made in a kind of pharmaceutical composition and its preparation process for treating reversible obstructive airways disease
Property obstructive airway diseases pharmaceutical composition raw material include salmeterol, it is beclomeasone propionate, filler, disintegrant, steady
Determine agent, adhesive, accelerating agent, lubricant and solubilizer；
The preparation method of the pharmaceutical composition of the treatment reversible obstructive airways disease is made, comprises the following steps that：
（1）It by salmeterol and filler, disintegrant under the rotating speed of 300-500r/min, is uniformly mixed, crushes, cross 100-
The sieve of 200 mesh obtains the compound particles of 100-200 mesh；
（2）In adhesive and stabilizer, the 2-4 times of medical purified water measured is added, stirs evenly and makes it completely dissolved, obtain molten
Liquid is spare；
（3）It is 1 that volume ratio, which is added, in accelerating agent and solubilizer:In the purified water and ethyl alcohol of 2-4, and beclomeasone propionate is added,
It is uniformly mixing to obtain granulation liquid, granulation liquid is added to step（1）In obtained compound particles, stir evenly, filtering,
Granulation, obtains wet granular, and wet granular is dried to obtain dry particl at 60-80 DEG C, controls dry particl free moisture≤1.2%；It will
The dry particl crosses the sieve of 20-40 mesh, obtains the dry particl of 20-40 mesh；
（4）To step（3）Step is added in the dry particl of the obtained 20-40 mesh（2）Obtained solution, stirs evenly, and obtains
To mixture；
（5）By step（4）After lubricant is added in obtained mixed powder, put into fluid bed it is dry-mixed, be preheated to temperature of charge
Start to spray into binder solution progress pelletizing press sheet up to 50 DEG C, and the tabletting is coated, obtain medical treatment reversible obstruction
The tablet of the pharmaceutical composition of property airway disorders.
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
The filler be lactose, microcrystalline cellulose, konjaku glucomannan, pregelatinized starch, D-sorbite, calcium phosphate,
It is one or more in mannitol, glucose, preferably lactose, microcrystalline cellulose, konjaku glucomannan.
The disintegrant is sodium carboxymethyl starch, low substituted hydroxy-propyl methylcellulose, dried starch, crosslinked polyethylene pyrroles
It is one or more in alkanone, gas-producing disintegrant, preferably sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone；The stabilizer
To be one or more in sodium chloride, amino acid, sodium citrate, preferably citric acid sodium.
Described adhesive is fibrinogenolysis liquid, polyvinylpyrrolidone, PVPK30, hypromellose, shallow lake
It is one or more in slurry, preferred fibrinogenolysis liquid；The accelerating agent is deoxysodium cholate, polyglycol ether, nitre
It is one or more in sour Soquad, estradiol, dimethylformamide, dodecyl methyl sulfoxide, preferably polyglycol ether,
Isosorbide Nitrate.
The lubricant is stearic acid, magnesium stearate, calcium stearate, one or more in talcum powder, preferably stearic
Sour magnesium, calcium stearate.
The solubilizer is in lauryl sodium sulfate, poloxamer, beta-cyclodextrin and its derivative, polysorbate
It is one or more, preferred beta-cyclodextrin.
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
Compared with prior art, the present invention having the advantages that：
Preparation process of the present invention is reasonable, and drug safety is high, stability is strong, for the treatment energy of reversible obstructive airways disease
Enough promote Airway Remodeling, strengthen broncho-pulmonary function of organization, is suitble to large-scale industrial production.
Description of the drawings
Attached drawing 1 is the healing statistical form of experimental group and control group disease after medicining cycle after medication.
Attached drawing 2 be after medication experimental group and control group in medicining cycle to the cure rate statistical form of disease.
Specific implementation mode
Present invention is further elaborated in following combination specific embodiment.
Embodiment 1
It is reversible that the treatment is made in a kind of pharmaceutical composition and its preparation process for treating reversible obstructive airways disease
The raw material and usage percentage of the pharmaceutical composition of property obstructive airway diseases are as follows：
；
The preparation method of the pharmaceutical composition of the treatment reversible obstructive airways disease is made, comprises the following steps that：
（1）It by salmeterol and filler, disintegrant under the rotating speed of 300-500r/min, is uniformly mixed, crushes, cross 100-
The sieve of 200 mesh obtains the compound particles of 100-200 mesh；
（2）In adhesive and stabilizer, the 2-4 times of medical purified water measured is added, stirs evenly and makes it completely dissolved, obtain molten
Liquid is spare；
（3）It is 1 that volume ratio, which is added, in accelerating agent and solubilizer:In the purified water and ethyl alcohol of 2-4, and beclomeasone propionate is added,
It is uniformly mixing to obtain granulation liquid, granulation liquid is added to step（1）In obtained compound particles, stir evenly, filtering,
Granulation, obtains wet granular, and wet granular is dried to obtain dry particl at 60-80 DEG C, controls dry particl free moisture≤1.2%；It will
The dry particl crosses the sieve of 20-40 mesh, obtains the dry particl of 20-40 mesh；
（4）To step（3）Step is added in the dry particl of the obtained 20-40 mesh（2）Obtained solution, stirs evenly, and obtains
To mixture；
（5）By step（4）After lubricant is added in obtained mixed powder, put into fluid bed it is dry-mixed, be preheated to temperature of charge
Start to spray into binder solution progress pelletizing press sheet up to 50 DEG C, and the tabletting is coated, obtain medical treatment reversible obstruction
The tablet of the pharmaceutical composition of property airway disorders.
Embodiment 2
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
The step of preparation process of the present embodiment such as embodiment 1.
Embodiment 3
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
The step of preparation process of the present embodiment such as embodiment 1.
Embodiment 4
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
The step of preparation process of the present embodiment such as embodiment 1.
Embodiment 5
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
The step of preparation process of the present embodiment such as embodiment 1.
Embodiment 6
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
The step of preparation process of the present embodiment such as embodiment 1.
Embodiment 7
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
The step of preparation process of the present embodiment such as embodiment 1.
Embodiment 8
Raw material and the usage percentage that the pharmaceutical composition of the treatment reversible obstructive airways disease is made are as follows：
。
The step of preparation process of the present embodiment such as embodiment 1.
One, the toxicity test of animal-use drug：
1, test medicine selects：
（1）Experimental group medication：The pharmaceutical composition of present invention treatment reversible obstructive airways disease is pressed 1:10 ratio with
Normal saline at normal saline suspension.
（2）Control group medication：With the physiological saline of experimental group medication equivalent.
2, acute toxicity test：
（1）Rat 120, half male and half female are chosen, weight 250-350g at least raises and train observation 1 week, records the row of rat before experiment
For activity, diet, weight and mental status, acute toxicity test is carried out.Rat is randomly divided into two groups, i.e. experimental group and control
Fasting 6 hours again are given after test medicine in group, fasting 12 hours before testing.
（2）Take the normal saline suspension of experimental group medication by the perfusion amount that gavage volume is 60ml/kg to experimental group
60 rats carry out perfusion；It is administered 3 times within one day, delivery time 7 hours is observed continuously 20 days after administration, and records rat
Toxic reaction and death toll.
（6）Take the normal saline in control group medication by the perfusion amount that gavage volume is 60ml/kg to control group
60 rats carry out perfusion；It is administered 3 times within one day, delivery time 7 hours is observed continuously 20 days after administration, to every rat
It should all examine and record in detail the toxic reaction and death toll of rat.
3, experimental result：
Compared with the control group, rat has no that notable difference, experiment are observed continuously 20 days after experimental group administration, rat body situation,
Diet, drinking-water, body weight increase are normal, illustrate the pharmaceutical composition of present invention treatment reversible obstructive airways disease to rat
Non-toxic after long-term administration, application is safe.
3, the toxicity test of repetitively administered（Long term toxicity test）：
（1）Rat 120, half male and half female are chosen, weight 200-300g at least raises and train observation 1 week, records the row of rat before experiment
For activity, diet, weight and mental status, acute toxicity test is carried out.Rat is randomly divided into two groups, i.e. experimental group and control
Fasting 6 hours again are given after test medicine in group, fasting 12 hours before testing.
（2）Take the normal saline suspension of experimental group medication by the perfusion amount that gavage volume is 60ml/kg to experimental group
80 rats carry out perfusion, and 2 times a day, delivery time 8 hours, continuous use is discontinued 2 weeks after 18 weeks, carries out experiment sight
It examines.
（3）Take the normal saline in control group medication by the perfusion amount that gavage volume is 60ml/kg to control group
80 rats carry out perfusion, and 2 times a day, delivery time 8 hours, continuous use is discontinued 2 weeks after 18 weeks, carries out experiment sight
It examines.
Experimental result：
Oral solution of the present invention is to the hair of rat, behavior, stool and urine, weight, organ weights, blood picture, hepatic and renal function, blood glucose, blood
The indexs such as fat all have no significant effect, and internal organs naked eyes are without finding that abnormal variation, histological indications show each internal organs of rat
Nothing is substantially change；Illustrate the pharmaceutical composition of present invention treatment reversible obstructive airways disease to nothing after rat long-term administration
Toxicity, also without abnormal reaction after drug withdrawal, application is safe.
Two, medicine property of medicine is tested：
1, test medicine selects：
（1）Experimental group medication：The present invention treats the pharmaceutical composition of reversible obstructive airways disease.
（2）Control group medication：The salmeterol powder of certain pharmaceutical factory production.
2, experimenter's mass selection is selected：
The reversible obstructive airways Disease 80 for extracting our hospital clinic, by patient press its age, gender, course of disease etc. by its
It is divided into experimental group and control group, every group of patient 40.Control group man 22, female 18, age 18-45 Sui, average age
31.2 years old；Experimental group man 23, female 17, age 19-43 Sui, average age 32.3 years old.
3, usage and dosage：
（1）Experimental group medication：Dosage is 300mg, 2 times a day, is taken orally, and (before the meal or at least 2 hours postprandial) is administered at empty stomach,
Continuous medication 10 days.
（2）Control group medication：Dosage is 300mg, and 2 times a day, imbedibility medication is (before the meal or postprandial at least 2 small
When), continuous medication 10 days.
4, observation item：
Observe clinical symptoms and sign：Including panting, shortness of breath, cough, the symptoms such as uncomfortable in chest, symptom press without, slight, moderate, severe
It is divided into 0-3 grades.
5, result：
As shown in attached drawing 1, attached drawing 2, after taking medicine 10 days, the clinical symptoms of experimental group and control group patient all gradually improve, experiment
It is 5 total to cure patient in medication the 4th day by 40 patients of group（12.5%）, in medication the 6th day, it is 13 total to cure patient
（32.5%）, in medication the 8th day, it is 22 total to cure patient（55%）, in medication the 10th day, it is 38 total to cure patient（95%）,
Slight each 1 of moderate patient, continues medication 2 days, it is 39 total to cure patient（97.5%）, after taking medicine 15 days, patient all controls
More；It is 1 total to cure patient in medication the 4th day by 40 patients of control group（2.5%）, in medication the 6th day, it is total to cure patient
Meter 5（12.5%）, in medication the 8th day, it is 16 total to cure patient（40.0%）, in medication the 10th day, cure patient total 25
Example（62.5%）, patients with mild 11（27.5%）, moderate patient 3（7.5%）, continue medication 2 days, it is 32 total to cure patient
（80%）, after taking medicine 15 days, it is 36 total to cure patient（90%）.
Three, pharmaceutical composition of the present invention acts on reversible obstructive airways Disease Intervention and tests
1, purpose：
Observe the Variation Features of reversible obstructive airways disease rat model broncho-pulmonary metaplasia growth factor and collagen
And their relationship, inquire into intervention effect of the present invention to broncho-pulmonary tissue.
2, experimental design：
（1）Rat 160, half male and half female are chosen, weight 200-350g at least raises and train observation 1 week, records the row of rat before experiment
For activity, diet, weight and mental status, acute toxicity test is carried out.Rat is randomly divided into two groups, i.e. experimental group and control
Fasting 6 hours again are given after test medicine in group, fasting 12 hours before testing.
（2）Control group is that tracheae injects lipopolysaccharides.
（3）Experimental group is the treatment group of the medicine composite for curing of present invention treatment reversible obstructive airways disease.
（4）After drug is fed 5 weeks, lungs are sliced and carry out Hematoxylin-eosin（HE）Dyeing observation broncho-pulmonary group
The pathological characters knitted, Masson dye the collagen content for implementing broncho-pulmonary tissue, and immunohistochemical staining detects TGF β 1, I type glue
Original, type III collagen, the expression in broncho-pulmonary.
3, conclusion：
Broncho-pulmonary tissue collagen deposition increase be reversible obstructive airways disease Airway Remodeling important pathological change, I types
Collagen, type III collagen and TGF β 1 increase in reversible obstructive airways disease broncho-pulmonary tissue expression, and I type glue
Former, type III collagen and TGF β 1 are proportionate, and show that TGF β 1 play important work in reversible obstructive airways disease Airway Remodeling
With.
Pharmaceutical composition of the present invention can reduce type i collagen, type III collagen and TGF β 1 in reversible obstructive airways disease
The expression rate of sick broncho-pulmonary tissue.
It is obvious to a person skilled in the art that invention is not limited to the details of the above exemplary embodiments, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of from which, the present embodiments are to be considered as illustrative and not restrictive, and the scope of the present invention is by appended right
It is required that rather than above description limit, it is intended that all changes that will be fallen within the meaning and scope of the equivalent requirements of the claims
Change is included within the present invention.Any label in claim should not be considered as and be limited the claims involved.
Based on the embodiments of the present invention, those of ordinary skill in the art are obtained without making creative work
The every other embodiment obtained, shall fall within the protection scope of the present invention.
Claims (9)
1. a kind of pharmaceutical composition and its preparation process for treating reversible obstructive airways disease, it is characterised in that：System
Raw material at the pharmaceutical composition of the treatment reversible obstructive airways disease includes salmeterol, beclomeasone propionate, fills out
Fill agent, disintegrant, stabilizer, adhesive, accelerating agent, lubricant and solubilizer；
The preparation method of the pharmaceutical composition of the treatment reversible obstructive airways disease is made, comprises the following steps that：
（1）It by salmeterol and filler, disintegrant under the rotating speed of 300-500r/min, is uniformly mixed, crushes, cross 100-
The sieve of 200 mesh obtains the compound particles of 100-200 mesh；
（2）In adhesive and stabilizer, the 2-4 times of medical purified water measured is added, stirs evenly and makes it completely dissolved, obtain molten
Liquid is spare；
（3）It is 1 that volume ratio, which is added, in accelerating agent and solubilizer:In the purified water and ethyl alcohol of 2-4, and beclomeasone propionate is added,
It is uniformly mixing to obtain granulation liquid, granulation liquid is added to step（1）In obtained compound particles, stir evenly, filtering,
Granulation, obtains wet granular, and wet granular is dried to obtain dry particl at 60-80 DEG C, controls dry particl free moisture≤1.2%；It will
The dry particl crosses the sieve of 20-40 mesh, obtains the dry particl of 20-40 mesh；
（4）To step（3）Step is added in the dry particl of the obtained 20-40 mesh（2）Obtained solution, stirs evenly, and obtains
To mixture；
（5）By step（4）After lubricant is added in obtained mixed powder, put into fluid bed it is dry-mixed, be preheated to temperature of charge
Start to spray into binder solution progress pelletizing press sheet up to 50 DEG C, and the tabletting is coated, obtain medical treatment reversible obstruction
The tablet of the pharmaceutical composition of property airway disorders.
2. a kind of pharmaceutical composition and its preparation work for treating reversible obstructive airways disease according to claim 1
Skill, it is characterised in that：The raw material and dosage percentage of the pharmaceutical composition of the treatment reversible obstructive airways disease is made
Than as follows：
。
3. a kind of pharmaceutical composition and its preparation work for treating reversible obstructive airways disease according to claim 1
Skill, it is characterised in that：The raw material and dosage percentage of the pharmaceutical composition of the treatment reversible obstructive airways disease is made
Than as follows：
。
4. according to any one of claim 1-3 it is described it is a kind of for treat reversible obstructive airways disease pharmaceutical composition and
Its preparation process, it is characterised in that：The filler is lactose, microcrystalline cellulose, konjaku glucomannan, pregelatinized starch, mountain
It is one or more in pears sugar alcohol, calcium phosphate, mannitol, glucose, preferably lactose, microcrystalline cellulose, konjaku glucomannan.
5. according to any one of claim 1-3 it is described it is a kind of for treat reversible obstructive airways disease pharmaceutical composition and
Its preparation process, it is characterised in that：The disintegrant be sodium carboxymethyl starch, low substituted hydroxy-propyl methylcellulose, dried starch,
It is one or more in crosslinked polyvinylpyrrolidone, gas-producing disintegrant, it is excellent
Select sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone；The stabilizer is in sodium chloride, amino acid, sodium citrate
It is one or more, preferably citric acid sodium.
6. according to any one of claim 1-3 it is described it is a kind of for treat reversible obstructive airways disease pharmaceutical composition and
Its preparation process, it is characterised in that：Described adhesive is fibrinogenolysis liquid, polyvinylpyrrolidone, PVPK30, hydroxypropyl
It is one or more in methylcellulose, starch slurry, preferred fibrinogenolysis liquid；The accelerating agent be deoxysodium cholate,
It is one or more in polyglycol ether, Isosorbide Nitrate, estradiol, dimethylformamide, dodecyl methyl sulfoxide, it is excellent
Select polyglycol ether, Isosorbide Nitrate.
7. according to any one of claim 1-3 it is described it is a kind of for treat reversible obstructive airways disease pharmaceutical composition and
Its preparation process, it is characterised in that：The lubricant be stearic acid, magnesium stearate, calcium stearate, one kind in talcum powder or
It is a variety of, preferably magnesium stearate, calcium stearate.
8. according to any one of claim 1-3 it is described it is a kind of for treat reversible obstructive airways disease pharmaceutical composition and
Its preparation process, it is characterised in that：The solubilizer be lauryl sodium sulfate, poloxamer, beta-cyclodextrin and its derivative,
It is one or more in polysorbate, preferred beta-cyclodextrin.
9. according to any one of claim 1-8 it is described it is a kind of for treat reversible obstructive airways disease pharmaceutical composition and
Its preparation process, it is characterised in that：Be made it is described treatment reversible obstructive airways disease pharmaceutical composition raw material and
Usage percentage is as follows：
。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810229148.0A CN108379244A (en) | 2018-03-20 | 2018-03-20 | A kind of pharmaceutical composition and its preparation process for treating reversible obstructive airways disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810229148.0A CN108379244A (en) | 2018-03-20 | 2018-03-20 | A kind of pharmaceutical composition and its preparation process for treating reversible obstructive airways disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108379244A true CN108379244A (en) | 2018-08-10 |
Family
ID=63067781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810229148.0A Pending CN108379244A (en) | 2018-03-20 | 2018-03-20 | A kind of pharmaceutical composition and its preparation process for treating reversible obstructive airways disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108379244A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530618A (en) * | 2009-04-13 | 2009-09-16 | 莫始平 | Pharmaceutical composition for the treatment of chronic obstructive pulmonary disease and bronchial asthma |
-
2018
- 2018-03-20 CN CN201810229148.0A patent/CN108379244A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530618A (en) * | 2009-04-13 | 2009-09-16 | 莫始平 | Pharmaceutical composition for the treatment of chronic obstructive pulmonary disease and bronchial asthma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527281A (en) | Application of andrographolide in pharmaceutical preparations for the treatment of inflammatory bowel disease, andrographolide enteric target micropellets and method for producing the same | |
| CN108904489A (en) | The purposes of the preventing respiratory diseases associated with inflammation of 3,4 ' flavonol of 5,7- methoxyl group | |
| CN113116907A (en) | Medical application of cycloastragenol | |
| CN108379244A (en) | A kind of pharmaceutical composition and its preparation process for treating reversible obstructive airways disease | |
| CN115990223B (en) | Application of composition in preparing medicine for assisting in treating chronic obstructive pulmonary disease | |
| CN103520096A (en) | Process for producing terbutaline sulfate injection | |
| CN101069688A (en) | Medicine composition containing theocin-like medicines and vitamin K | |
| CN105147670B (en) | The application of a kind of compound in the medicine of preparation treatment COPD | |
| CN108721296B (en) | A kind of compound is treating or preventing the purposes in altitude sickness | |
| CN109200051A (en) | Purposes of the huperzine and the like as treatment diseases associated with inflammation drug | |
| CN102716128A (en) | Pharmaceutical composition for treating asthma | |
| CN108653292B (en) | A kind of compound is treating or preventing the purposes in altitude sickness | |
| CN111494546B (en) | Pharmaceutical composition with effect of relieving gouty pain | |
| CN104829467A (en) | Ambroxol hydrochloride dihydrate compound | |
| CN108904501B (en) | A kind of compound is treating or preventing the purposes in altitude sickness | |
| CN107823172A (en) | A kind of choline theophyllinate piece and preparation method thereof | |
| CN105770867A (en) | Tablets for treating tuberculous pericarditis and preparation method thereof | |
| CN104434861B (en) | Ambroxol hydrochloride osmotic pump controlled release tablet and preparation method thereof | |
| CN108465009A (en) | Saorilao removing heat from the lung to relieve cough capsule particle fluidized bed coating technique research and its clinical application | |
| CN113134000B (en) | Pharmaceutical composition containing relaxing smooth muscle | |
| CN105796522A (en) | Pulsatile controlled-release tablet containing fluticasone furoate and vilanterol and preparation method thereof | |
| CN110215510A (en) | Application of the Polaprezinc in preparation treatment or mitigation caused by radiotherapy and chemotherapy injury to alimentary tract drug | |
| Seddon et al. | Long term survival after treatment of disseminated T cell lymphoma presenting with tracheal obstruction in a patient with coeliac disease. | |
| CN105412126A (en) | Composition containing salazosulfapyridine and application of composition in preparation of medicine for treating ulcerative colitis | |
| CN105380953B (en) | Applications of the physalin P in the medicine for preparing treatment COPD |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180810 |